George Georgiou

• Dula D. Cockrell Centennial Chair in Engineering #2: 2019-Present
• Professor, Molecular Biosciences, U. Texas, Austin: 2005-Present
• Professor, Dept. of Chemical Engineering, U. Texas, Austin: 1995-Present
• Professor, Dept of Biomedical Engineering, U. Texas, Austin: 2001-Present
• Member, Institute for Molecular and Cellular Biology, U. Texas, Austin: 1994-2021
• Associate Professor, Dept. of Chemical Engineering, U. Texas, Austin: 1991-1994
• Assistant Professor, Dept. of Chemical Engineering, U. Texas, Austin: 1986-1991

Georgiou's research is focused on understanding the serological antibody repertoire (as well as the BCR and TCR repertoires) in human health and disease the discovery and preclinical development of enzyme and antibody therapeutics for cancer and for inborn errors of metabolism.

Current Projects include:

1. 1. The discovery, early development and preclinical validation of protein therapeutics for the treatment of cancer, inborn errors of metabolism disorders and other diseases. Our lab has invented and played a key role in the early development of one FDA approved therapeutic protein and four proteins that are currently in clinical trials.
2. 2. Molecular level understanding of human antibody immunity. We have developed technologies for determining the identity (sequence), relative abundance and function of the ensemble of circulating antibodies that are elicited as a result of infection, vaccination or in disease states such as cancer and autoimmunity. The application of these technologies is providing important insights that inform vaccine design and aid in the discovery of very potent human therapeutic antibodies.
3. 3. Engineering of the Fc domain of therapeutic antibodies to develop, “second generation” improved therapeutics and to expand our understanding of how antibodies interact with other components of the immune system to help eradicate disease-causing cells.

Dr. Georgiou is the author of >300 research publications and co-inventor of >150 issued or pending US patents, more than 75% of which (comprising 27 distinct technology suites) have been licensed to 31 pharma & biotech companies.  He founded GGMJD (1999; acquired by Maxygen in 2000) and two NSDQ traded companies (NASDAQ: now trading as SYRE and IMA)  and served in the Board of Directors of both companies.